Hirva Mamdani, MD
Hematology & Oncology · Detroit, MINPI 1437446820
Payments from drug & device makers
Across 651 payments — averaging $14,662 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4.4M
- Merck$2.8M
- Pfizer$1.3M
- Mirati Therapeutics, Inc.$547K
- AbbVie$87K
- GSK$78K
- plus $314K from 18 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $4,396,875 |
| Merck | 98 | $2,823,442 |
| Pfizer | 229 | $1,299,309 |
| Mirati Therapeutics, Inc. | 75 | $547,018 |
| AbbVie | 25 | $86,688 |
| GSK | 46 | $77,616 |
| Boehringer Ingelheim | 5 | $54,040 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $47,559 |
| Acerta Pharma LLC | 1 | $40,492 |
| Seagen Inc. | 2 | $40,420 |
| Roche Products Limited | 10 | $25,574 |
| Spectrum Pharmaceuticals Inc. | 9 | $25,435 |
| Tesaro, Inc. | 10 | $19,663 |
| E.r. Squibb & Sons, L.L.C. | 7 | $18,820 |
| Incyte Corporation | 15 | $18,029 |
| Genentech, Inc. | 10 | $13,956 |
| Astrazeneca UK Limited | 2 | $3,740 |
| Genentech USA, Inc. | 7 | $3,350 |
| Daiichi Sankyo Inc. | 1 | $1,290 |
| Boehringer Ingelheim International GmbH | 1 | $785 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 8 | $750 |
| Johnson & Johnson | 3 | $129 |
| Genmab U.S., Inc. | 1 | $66 |
| Amgen | 1 | $13 |
How this compares
$9,545,059 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Detroit
- Jeffrey ZonderDetroit$8.2M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
- Igor RybkinDetroit$2.4M
- Anthony ShieldsDetroit$2.3M
- Mohammed Al HallakDetroit$1.7M
- Yusra ShaoDetroit$1.5M
- Jay YangDetroit$1.4M
- Hadeel AssadDetroit$1.2M
- Wasif SaifDetroit$885K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.